9.1.3. Drugs used in hypoplastic, haemolytic, and renal anaemias
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure. This is the preferred Formulary agent for this indication.
Restrictions:
Restricted to specialist use only in accordance with the Prescribing Notes below.
Prescribing Notes:
Formulary indications:
- Treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions when deferoxamine therapy is contraindicated or inadequate
- Treatment of myeloplastic syndrome (MDS) in patients with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk when deferoxamine therapy is contraindicated or inadequate in accordance with regional protocol (in development)
It is not recommended by SMC for:
- Treatment of patients with chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes and is non-Formulary for these indications.
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure.
Prescribing Notes:
- Prescribe by brand name.
- The treatment of symptomatic anaemia in adults with low or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoetin is not recommended for use by the SMC and is non-Formulary.
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure.
Prescribing Notes:
Prescribe by brand name.
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure.
Restrictions:
The treatment of symptomatic anaemia associated with chronic kidney disease (CKD) is restricted to specialist use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation.